Decoy Therapeutics Provides Third Quarter 2026 Business Update
Decoy Therapeutics reports Q3 2026 progress, including an optimized pan-coronavirus lead with once-weekly dosing potential and $8.1 million in cash.
Decoy Therapeutics reports Q3 2026 progress, including an optimized pan-coronavirus lead with once-weekly dosing potential and $8.1 million in cash.